Top

Published in:

01-04-2018 | Review Article

Reactive arthritis: update 2018

Authors: A. García-Kutzbach, J. Chacón-Súchite, H. García-Ferrer, I. Iraheta

Published in: Clinical Rheumatology | Issue 4/2018

Abstract

At this time, reactive arthritis (ReA) is considered to be part of the spectrum of the spondyloarthritis, previously known as Reiter’s syndrome, and refers to an infection induced systemic illness, characterized by a sterile synovitis occurring in a genetically predisposed individual, secondary to an infection localized in a distant organ/system, but also accompanied with multiple extra articular manifestations.

Keynan Y, Rimar D (2008) Reactive arthritis—the appropriate name. Isr Med Assoc J 10(4):256–258PubMed

Panush R, Wallace D, Dorff R, Engleman E (2007) Retraction of the suggestion to use the term «Reiter’s syndrome» sixty-five years later. Arthritis Rheum 56(2):693–694. https://doi.org/10.1002/art.22374 CrossRefPubMed

Stavropoulos P, Soura E, Kanelleas A, Katsambas A, Antoniou C (2015) Reactive arthritis. J Eur Acad Dermatology Venereol 29(3):415–424. https://doi.org/10.1111/jdv.12741 CrossRef

Hannu T (2011) Reactive arthritis. Best Pract Res Clin Rheumatol 25(3):347–357. https://doi.org/10.1016/j.berh.2011.01.018 CrossRefPubMed

Colmegna I, Cuchacovich R, Espinoza L (2004) HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clin Microbiol Rev 17(2):348–369. https://doi.org/10.1128/CMR.17.2.348 CrossRefPubMedPubMedCentral

Gupta R, Misra R (2016) Microbe-triggered arthropathies: reactive arthritis and beyond. Int J Rheum Dis 19(5):437–439. https://doi.org/10.1111/1756-185X.12920 CrossRefPubMed

Lopez Férez F, García Novo E (1986) Tratados hipocráticos. (eds) Gredos, Madrid, España

Allison D (1980) Christopher Columbus: first case of Reiter’S disease in the old world? Lancet 316(8207):1309. https://doi.org/10.1016/S0140-6736(80)92381-8 CrossRef

Carter J, Hudson A (2009) Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin N Am 35(1):21–44. https://doi.org/10.1016/j.rdc.2009.03.010 CrossRef

10.

Manasson J, Shen N, García H, Ubeda C, Iraheta I, Heguy A, Von Feldt J, Espinoza L, García Kutzbach A, Segal L, Ogdie A, Clemente J, Sher J (2017) Gut microbiota perturbations in reactive arthritis and post-infectious Spondyloarthritis arthritis. Rheum. https://doi.org/10.1002/art.40359 [Epub ahed of print]

11.

Ehrenfeld M (2010) Geoepidemiology: the environment and spondyloarthropathies. Autoimmun Rev 9(5):A325–A329. https://doi.org/10.1016/j.autrev.2009.11.012 CrossRefPubMed

12.

Szamocki S, Martyn-hemphill C, Green J (2016) Reactive arthritis: can’t see, can’t pee, can’t climb a tree. Trends Urol Men’s Heal 7(1):17–20. https://doi.org/10.1002/tre.501 CrossRef

13.

García-Kutzbach A, Montenegro A, Iraheta I, Bará C, Saénz R (2011) Epidemiology of spondyloarthropathies in Central America. Am J Med Sci 341(4):295–297. https://doi.org/10.1097/MAJ.0b013e31820f8cf1 CrossRefPubMed

14.

Brewerton D, Hart F, Nicholls A, Caffrey M, James D, Sturrock R (1973) Ankylosing spondylitis and HlA 27. Lancet 301(7809):904–907. https://doi.org/10.1016/S0140-6736(73)91360-3 CrossRef

15.

Schlosstein L, Terasaki P, Bluestone R, Pearson C (1973) High association of an HLA antigen, W27 with ankylosing spondylitis. N Engl J Med 288(14):704–705. https://doi.org/10.1056/NEJM197304052881403 CrossRefPubMed

16.

Vazquez-Torres A, Vallance B, Bergman M, Finlay B, Cookson B, Jones-Carson J et al (2004) Toll-like receptor 4 dependence of innate and adaptive immunity to salmonella: importance of the Kupffer cell network. J Immunol 172(10):6202–6208. https://doi.org/10.4049/jimmunol.172.10.6202 CrossRefPubMed

17.

Reveille JD (2014) An update on the contribution of the MHC to as susceptibility. Clin Rheumatol 33(6):749–757. https://doi.org/10.1007/s10067-014-2662-7 CrossRefPubMedPubMedCentral

18.

Tsui F, Xi N, Rohekar S, Riarh R, Bilotta R, Tsui H et al (2008) Toll-like receptor 2 variants are associated with acute reactive arthritis. Arthritis Rheum 58(11):3436–3438. https://doi.org/10.1002/art.23967 CrossRefPubMed

19.

Rihl M, Klos A, Köhler L, Kuipers J (2006) Reactive arthritis. Best Pract Res Clin Rheumatol 20(6):1119–1137. https://doi.org/10.1016/j.berh.2006.08.008 CrossRefPubMed

20.

Denison H, Curtis E, Clynes M, Bromhead C, Dennison E, Grainger R (2016) The incidence of sexually acquired reactive arthritis: a systematic literature review. Clin Rheumatol 35(11):2639–2648. https://doi.org/10.1007/s10067-016-3364-0 CrossRefPubMedPubMedCentral

21.

Asquith M, Rosenbaum J (2016) The interaction between host genetics and the microbiome in the pathogenesis of spondyloarthropathies. Curr Opin Rheumatol 28(4):405–412. https://doi.org/10.1097/BOR.0000000000000299 CrossRefPubMed

22.

Reveille JD (2012) Genetics of spondyloarthritis—beyond the MHC. Nat Rev Rheumatol 8(5):296–304. https://doi.org/10.1038/nrrheum.2012.41 CrossRefPubMed

23.

Pope J, Krizova A, Garg A, Thiessen-Philbrook H, Ouimet J (2007) Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum 37(1):48–55. https://doi.org/10.1016/j.semarthrit.2006.12.006 CrossRefPubMedPubMedCentral

24.

Zeidler H, Hudson A (2016) Coinfection of chlamydiae and other bacteria in reactive arthritis and spondyloarthritis: need for future research. Microorganisms 4(3):30. https://doi.org/10.3390/microorganisms4030030 CrossRefPubMedCentral

25.

Carter J, Inman R (2011) Chlamydia-induced reactive arthritis: hidden in plain sight? Best Pract Res Clin Rheumatol 25(3):359–374. https://doi.org/10.1016/j.berh.2011.05.001 CrossRefPubMed

26.

Gaston J (2005) Shigella induced reactive arthritis. Ann Rheum Dis 64(4):517–518. https://doi.org/10.1136/ard.2004.030395 CrossRefPubMedPubMedCentral

27.

Cargnelutti E, Di Genaro M (2013) Reactive arthritis: from clinical features to pathogenesis. Int J Clin Med 4(12):20–30. https://doi.org/10.4236/ijcm.2013.412A2004 CrossRef

28.

Garcia H, Azan A, Iraheta I, Von Feldt J, Espinoza L, Manasson J, Scher J, García Kutzbach A (2017) Potential risk factors for reactive arthritis and persistence of symptoms at 2 years: a case-control study with longitudinal follow-up. Clin Rheumatol. https://doi.org/10.1007/s10067-017-3911.3 [Epub ahed of print]

29.

Van de Wiele T, Van Praet J, Marzorati M, Drennan M, Elewaut D (2016) How the microbiota shapes rheumatic diseases. Nat Rev Rheumatol 12(7):398–411. https://doi.org/10.1038/nrrheum.2016.85 CrossRefPubMed

30.

Caminer A, Haberman R, Scher J (2017) Human microbiome, infections, and rheumatic disease. Clin Rheumatol 36(12):2645–2653. https://doi.org/10.1007/s10067-017-3875-3 CrossRefPubMed

31.

Brown J, Hazen S (2015) The gut microbial endocrine organ: bacterially-derived signals driving cardiometabolic diseases. Annu Rev Med 66(1):343–359. https://doi.org/10.1146/annurev-med-060513-093205 CrossRefPubMedPubMedCentral

32.

Eckburg P, Bik E, Bernstein C, Purdom E, Dethlefsen L, Sargent M, Gill S, Nelson K, Relman D (2005) Diversity of the human intestinal microbial flora. Science 308(5728):1635–1638. https://doi.org/10.1126/science.1110591 CrossRefPubMedPubMedCentral

33.

Blaser M, Bork P, Fraser C, Knight R, Wang J (2013) The microbiome explored: recent insights and future challenges. Nat Rev Microbiol 11(3):213–217. https://doi.org/10.1038/nrmicro2973 CrossRefPubMed

34.

Catrina A, Deane K, Scher J (2016) Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. Rheumatology 55(3):391–402. https://doi.org/10.1093/rheumatology/keu469 PubMed

35.

Wendling D, Prati C (2017) Spondyloarthritis: an expanding cast of cellular actors. Jt bone Spine:1–3. https://doi.org/10.1016/j.jbspin.2017.05

36.

Ericsson A, Hagan C, Davis D, Franklin C (2014) Segmented filamentous bacteria: commensal microbes with potential effects on research. Comp Med 64(2):90–98PubMedPubMedCentral

37.

Ji B, Nielsen J (2015) New insight into the gut microbiome through metagenomics. Adv Genomics Genet 5:77–91. https://doi.org/10.2147/AGG.S57215

38.

Ivanov I, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U et al (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139(3):485–498. https://doi.org/10.1016/j.cell.2009.09.033 CrossRefPubMedPubMedCentral

39.

Miossec P (2017) Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. RMD 3(1):e000284. https://doi.org/10.1136/rmdopen-2016-000284 CrossRef

40.

Riente L, Sedie A, Filippucci E, Iagnocco A, Meenagh G, Grassi W, Valesini G, Bombardieri S (2007) Ultrasound imaging for the rheumatologist IX. Ultrasound imaging in spondyloarthritis. Clin Exp Rheumatol 25(3):349–353PubMed

41.

Colmegna I, Espinoza L (2005) Recent advances in reactive arthritis. Curr Rheumatol Rep 7(3):201–207. https://doi.org/10.1007/s11926-996-0040-4 CrossRefPubMed

42.

Allen-Vercoe E, Reid G, Viner N, Gloor G, Hota S, Kim P, Lee C, O’Doherty K, Vanner S, Weewe S, Petrof E (2012) A Canadian working group report on fecal microbial therapy: microbial ecosystems therapeutics. Can J Gastroenterol 26(7):457–462. https://doi.org/10.1155/2012/213828

Title: Reactive arthritis: update 2018
Authors: A. García-Kutzbach
J. Chacón-Súchite
H. García-Ferrer
I. Iraheta
Publication date: 01-04-2018
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 4/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-018-4022-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Inflammatory tenosynovitis and enthesitis induced by immune checkpoint inhibitor treatment

Can we have an overall osteoarthritis severity score for the patellofemoral joint using magnetic resonance imaging? Reliability and validity

First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study

Correction to: Effect of daily low dose prednisone, divided or single daily dose, in the treatment of African Americans with early rheumatoid arthritis

Long-term outcomes of daily oral vs. pulsed intravenous cyclophosphamide in a non-trial setting in ANCA-associated vasculitis

Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage